CDC’s Proposed Opioid Prescribing Guideline: Does it Fall Short on Drug Testing?
April 18th 2022Last month, the Centers for Disease Control and Prevention shared a draft update to its Clinical Practice Guideline for Prescribing Opioids. The proposed revision comes as the nation’s overdose death rate reaches an all-time high, fueled largely by the economic and psychological strains and lack of healthcare access caused by COVID-19.
Read More
In this week's episode, Briana Contreras, editor of Managed Healthcare Executive, spoke with Dr. Paige Kilian, chief medical officer at Inovalon. In the discussion, Dr. Kilian broke down the current issues health plans are facing when it comes to risk adjustment and how it’s affecting members of these plans. She also shared some solutions that can help plans improve risk adjustment and quality programs with one in particular being health plans identifying care gaps through data and analytics.
Listen
5 Exacerbation-prone Phenotypes Were Discovered Among Asthma and COPD Patients
April 14th 2022Five phenotype clusters were discovered to be associated with the exacerbation, or worsening, of chronic inflammatory airway diseases of asthma and chronic obstructive pulmonary disease (COPD), according to a recent study published in PLOS ONE.
Read More
More Evidence of Mental Health Services Shifting to Telehealth: Health Affairs Study
April 13th 2022Findings published in the April issue of Health Affairs show a huge jump in telehealth visits, but the researchers also detected that a pattern that suggests that people with conditions such as schizophrenia did not make the switch to telehealth as readily as people with anxiety and some other disorders.
Read More
Finding a Way Forward for Public Health - Greater Investment, Greater Distrust
April 13th 2022“The most remarkable change in patterns of health during the (past) century has been the largely successful conquest of infectious diseases,” wrote Allan Brandt, Harvard medical historian, in “No Magic Bullet: A Social History of Venereal Disease in the United States Since 1880."
Read More
FDA Updates for Week of April 4, 2022
April 9th 2022The FDA approves novel therapy for schizophrenia and bipolar and grants accelerated approval to treat rare disorder. The agency also accepted the sBLA and has granted priority review for Actemra or the treatment of COVID-19 and has extended the PDUFA date for vutrisiran.
Read More
Humira Biosimilars Are Hitting the Market in 2023. Finally. But Will Prescriptions Follow?
April 7th 2022Marcus Snow, MD, , chair of the American College of Rheumatology’s Committee on Rheumatologic Care, discusses how additional clinical data and interchangeability designations could help build momentum for use of Humira (adalimumab) biosimilars when they start to arrive in 2023.
Read More